Publications and Patents

Access our publications on PubMed

NU undergraduate student; NU graduate student; ºNEU postdoctoral scholar.

  1. ºAmata, E.; Bland, N.D.; Campbell, R.K.; Pollastri, M.P. Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). Tetrahedron Letters. In press.
  2. Kozakov, K.; Hall, D.R.; Jehle, S.; Luo, L.; Ochiana, S.O.; Jones, E.V.; Pollastri, M.P.; Allen, K.N.; Whitty, A.; Vajda, S. Ligand Deconstruction: Why Some Fragment Binding Positions Are Conserved and Others Are Not. Proceedings of the National Academy of Science. In press.
  3. Shivanna S.; Kolandaivelu, K.; Moshe, S.; Novikov, O.; Balcells, M.; Zheng A.; Weinberg, J.; Francis, J.; Pollastri, M.P.; Edelman, E.R.; Sherr, D.H.; Chitalia, V.C. The aryl hydrocarbon receptor is a critical regulator of tissue factor stability and is a novel anti-thrombotic target in uremia. Journal of the American Society of Nephrology. In Press.
  4. Ochiana, S.O.; Bland, N.D.; Settimo, L.; Campbell, R.K.; Pollastri, M.P. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. Chemical Biology & Drug Design  2015, 85, 549-564.
  5. Woodring, J.L.; oPatel, G.; Erath, J.; Behera, R.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Sciotti, R.J.; Mensa-Wilmot, K.; Pollastri, M.P. Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria. MedChemComm. 2015, 6, 339-346.
  6. Silva, L.; Tanner, A.; Merritt, C.; Stuart, K.; Pollastri, M.P. Protein kinases as druggable targets in protozoan parasites. Chemical Reviews, 2014, 114, 1280–11304. Invited review.
  7. Diaz, R.; ºLuengo-Arratta, S.A.; ºSeixas, J.D.; ºAmata, E.; Devine, W.; Cordon-Obras, C.; Rojas-Barros, D.I.; Jimenez, E.; Ortega, F.; Crouch, S.; Colmenarejo, G.; Fiandor, J.M.; Martin, J.J.; Berlanga, M.; Gonzalez, S.; Manzano, P.; Navarro, M.; Pollastri, M.P. Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign. PLOS Neglected Tropical Diseases. 2014, 8, e3253.
  8. Parks, A.J.; Pollastri, M.P.; Hahn, M.E.; Stanford, E.A.; Franks, D.G; Haigh, S.E.; Narasimhan, S.; ºAshton, T.D.; Hopper, T.G.; Kozakov, D.; Beglov, D.; Vajda, S.; Schlezinger, J.J.; Sherr, D.H. In Silico Identification of an Aryl Hydrocarbon Receptor (AhR) Antagonist with Biological Activity In Vitro and In Vivo. Molecular Pharmacology 2014, 86, 593-608.
  9. ºAmata, E.; Bland, N.D.; Hoyt, C.T.; Settimo, L.; Campbell, R.K.; Pollastri, M.P. Repurposing human PDE4 inhibitors for neglected tropical diseases: Design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors. Bioorganic and Medicinal Chemistry Letters 2014, 24, 4084-4089.
  10. Gaun, V.; Patchen, B.; Volovetz, J.; Zhen, A.W.; Andreev, A.; Pollastri, M.P.; Fraenkel, P.G. A chemical screen identifies small molecules that regulate hepcidin expression. Blood Cells, Molecules and Diseases 2014, 53, 231-240.
  11. Galvin, B.D.; Li, Z.; Villemaine, E.; Poole, C.B.; Chapman, M.S.; Pollastri, M.P.; Wyatt, P.G.; Carlow, C.K.S. A target repurposing approach identifies N-myristoyltransferase as a new candidate drug target in filarial nematodes. PLOS Neglected Tropical Diseases 2014, 8, e3145
  12. Pollastri, M.P. Finding New Collaboration Models for Enabling Neglected Tropical Disease Drug Discovery. PLoS-Neglected Tropical Diseases 2014, 8, e2866.
  13. ºSeixas, J.D.; ºLuengo-Arratta, S.A.; Diaz, R.; Saldivia, M.; Rojas-Barros, D.I.; Manzano, P.; Gonzalez, S.; Berlanga, M.; Smith, T.K.; Navarro, M.; Pollastri, M.P. Establishment of a structure-activity relationship of the NVP-BEZ235 chemotype as a lead for African sleeping sickness. Journal of Medicinal Chemistry 2014, 57, 4834-4848.
  14. ºPatel, G.; Roncal, N.E.; Lee, P.J.; Leed, S.E.; Erath, J.; Rodriguez, A.; Sciotti, R.J.; Pollastri, M.P. Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery. MedChemComm  2014, 5, 655 – 658.
  15. Lowe, M.M.; Mold, J.E.; Kanwar, B.; Huang, Y.; Louie, A.; Hahn, M.E.; Pollastri, M.P.; ºWang, C.; ºPatel, G.; Frank, D.G.; Schlezinger, J.; Sherr, D.; Silverstone, A.E.; McCune, J.M. Identification of an Endogenous Aryl Hydrocarbon Receptor Ligand That Drives Th22 Differentiation. PLoS One 2014, 9, e87877.
  16. Woodring, J.L.;  Bland, N.D.; Ochiana, S.O.; Campbell, R.K.; Pollastri, M.P. Synthesis and assessment of catechol diether compounds as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1). Bioorganic and Medicinal Chemistry Letters 2013, 23, 5971-5974.
  17. ºPatel, G.; ºKarver, C.E.; Behera, R.; Guyett, P.; Edwards, P.; Roncal, N.E.; Mensa-Wilmot, K.; Pollastri, M.P. Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis. Journal of Medicinal Chemistry 2013, 56, 3820-3832.
  18. Andriani, G.; ºAmata, E.; Beatty, J.; Clements, Z.; Coffey, B.J.; Courtemanche, G.; Devine, W.; Erath, J.; Juda, C.E.; Wawrzak, Z.; Wood, J.; Lepesheva, G.I.; Rodriguez, A.; Pollastri, M.P. Antitrypanosomal lead discovery: Identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. Journal of Medicinal Chemistry 2013, 56, 2556-2567.
  19. Katiyar, S.; Kufareva, I.; Behera, R.; Ogata, Y.; Pollastri, M.P.; Abagyan, R;. Mensa-Wilmot, K. Lapatinib-binding Protein Kinases in the African Trypanosome: A General Method for Identification of Targets for Kinase-Directed Drugs in a Cell. PloS One 2013, 8, e56150.
  20. Ochiana, S.O.; Pandarinath, V.; Wang, Z.; Kapoor, R.; Ondrechen, M.J.; Ruben, L.; Pollastri, M.P. The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing. European Journal of Medicinal Chemistry 2013, 62, 777-784.
  21. ºWang, C.; ºAshton,  T.D.; Gustafson, A.; Bland, N.D.; Ochiana, S.O.; Campbell, R.K.; Pollastri, M.P. Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 1. Sildenafil analogs. Bioorganic and Medicinal Chemistry Letters 2012, 22, 2579-2581.
  22. Ochiana, S.O.; Gustafson, A.; Bland, N.D.; ºWang, C.; Russo, M.J.; Campbell, R.K.; Pollastri, M.P. Synthesis and evaluation of human phosphodiesterases (PDE) 5 inhibitor analogs as trypanosomal PDE inhibitors. 2. Tadalafil analogs. Bioorganic and Medicinal Chemistry Letters 2012, 22, 2582-2584.
  23. Bland, N. D.; ºWang, C.; Tallman, C.; Gustafson, A. E.; Wang, Z.; ºAshton, T. D.; Ochiana, S. O.; McAllister, G.; Cotter, K.; Fang, A. P.; Gechijian, G.; Garceau, N.; Gangurde, R.; Ortenberg, R.; Ondrechen, M. J.; Campbell, R. K.; Pollastri, M. P. Pharmacological Validation of Trypanosoma brucei Phosphodiesterases B1 and B2 as Druggable Targets for African Sleeping Sickness. Journal of Medicinal Chemistry 2011 54, 8188-8194.
  24. Diaz-Gonzalez, R.; Kuhlmann, F.M.; Galan-Rodriguez, C.; Madeira da Silva,L.; ºKarver, C.E.;Beverley, S.M.; Rodriguez,  A.; Navarro, M; Pollastri, M.P. The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing. PLoS-Neglected Tropical Diseases 2011, 5, e1297.
  25. Doan, T. L.; Pollastri, M.P.; Walters, M.A.; Georg, G.I. Progress in drug repositioning: Old drugs, new opportunities. Annual Reports in Medicinal Chemistry 2011, 46, 385-401. Invited review.
  26. Pollastri, M.P; Campbell, R.K. Target repurposing for neglected diseases. Future Medicinal Chemistry 2011, 3,1307-1315. Invited review.
  27. Shaw, B. F.; Arthanari, H.; Narovlyansky, M.; Durazo, A.; Frueh, D.P.; Pollastri, M. P.; Lee, A.; Bilgicer, B.; Gygi, S. P.; Wagner, G.; Whitesides, G. M. Neutralizing positive charges at the surface of a protein lowers its rate of amide hydrogen exchange without altering its structure or increasing its thermostability. Journal of the American Chemical Society 2010 132, 17411-17425.
  28. Pollastri, M. P. “Overview of the Rule of Five.” Current Protocols in Pharmacology. John Wiley & Sons, Inc.  2010, 49, 9.12.1–9.12.8. Invited review
  29. Pollastri, M. P.; Whitty, A.; Merrill, J. C., Tang, X. ºAshton, T. D.; Amar, S.  Identification and Characterization of Kava-derived Compounds Mediating TNF-α Suppression. Chemical Biology and Drug Design 2009, 74, 121-128.
  30. Bazin, M; Shi, H; Delaney, J.; Kline, B;, Zhu, Z.; Kuhn, C.; Berlioz, F.; Farley, K.; Fate, G.; Lam, W.; Walker, G.; Yu, L.; Pollastri, M.P. Efficient use of the iron ortho-nitrophenylporphyrin chloride to mimic biological oxidations of dimethylaminoantipyrine. Chemical Biology and Drug Design 2007, 70, 354-359.
  31. Pollastri, M. P. “Development of continuous flow synthesis for production of compounds for medicinal chemistry”, ChemTracts—Organic Chemistry 2007, 20, 199-209. Invited review
  32. Pollastri, M.P., Sagal, J.F., Chang, G., The Conversion of Alcohols to Halides Using a Filterable Phosphine Source. Tetrahedron Letters 2001, 35, 2459-2460.
  33. Pollastri, M.P., Porter, N.A., McIntosh, T.J., Simon, S.A., Synthesis, Structure, and Thermal Properties of 1,2-Dipalmitoylgalloylglycerol (DPGG), A Novel Self-Adhering Lipid. Chemistry and Physics of Lipids 2000, 104, 67-74.
  34. McIntosh, T.J., Pollastri, M.P., Porter, N.A., Simon, S.A, Polyphenols increase adhesion between lipid bilayers by forming interbilayer bridges, Basic Life Sciences 66(Plant Polyphenols 2) 1999, 451-470.
  35. Jones, P.B., Pollastri, M.P., Porter, N.A., 2-Benzoylbenzoic Acid: A Photolabile Mask for Alcohols and Thiols.  Journal of Organic Chemistry 1996, 61, 9455-9461.
  36. Curran, T.P., Pollastri, M.P., Abelleira, S.M., Messier, R.J., McCollum, T.A., Rowe, C.G., Loss of the tert-Butyloxycarbonyl (Boc) Protecting Group Under Basic Conditions. Tetrahedron Letters 1994, 35, 5409-5412.
  37. Curran, T.P., Smith, M.B., Pollastri, M.P., Cis-3,5-Dimethyl-3,5-Piperdinedicarboxylic Acid, An Amino Diacid Variant of Kemp’s Triacid. Tetrahedron Letters 1994, 35, 4515-4518.


  1. Pollastri, M.P., Mehta, N., Devine, W., Woodring, J., Swaminathan, U., Mensa-Wilmot, K. “Protozoan parasite growth inhibitors”. US Patent Application No. 14/660,662, 17 March 2015.
  2. Pollastri, M.P., Rodriguez, A. “Novel Anti Trypanosoma Cruzi Compounds That Inhibit TcCYP51” US Provisional Application No. 61/755,147  Jan. 22, 2013.
  3. Lewis, K., Conlon, B., Nelson, M.L., Pollastri, M.P., Dahl, T.A. “Methods of eradicating bacterial cell populations.” PCT/US12/31882
  4. Sherr, D.S., Pollastri, M.P., Schlezinger, J., Haigh Molina, S.E., Schaus, S.E., Giguere, J.R. “Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics.” PCT/US11/45526, U.S. Serial No. 13/812375
  5. Pollastri, M.P., Navarro, M., Beverley, S., Rodriguez, A. “Antiparasitic agents based on mTOR inhibitors” PCT/US11/43557
  6. Chang, G., Didiuk, M. T. Finneman, J. I., Garigiapati, R. S., Kelley, R. M., Perry, D. A., Ruggeri, R. B., Bechle, B. M., Pollastri, M. P. “Preparation of 1,2,4-substituted-1,2,3,4-tetrahydro-and 1,2-dihydroquinoline and 1,2,3,4-tetrahydroquinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity.” WO 2004085401.
  7. Bechle, B.M., Chang, G.C., Diduik, M., Garigipati, R.S., Kelley, R.M., Perry, D.A., Pollastri, M.P. Ruggeri, R.B. “Quinoline and quinoxaline compounds.” US11305874